Development of Radiation/Nuclear Medical Countermeasures (MCMs) And Biodosimetry Devices
ID: BAA-75N93024R00020Type: Solicitation
Overview

Buyer

HEALTH AND HUMAN SERVICES, DEPARTMENT OFNATIONAL INSTITUTES OF HEALTHNATIONAL INSTITUTES OF HEALTH NIAIDBETHESDA, MD, 20892, USA

NAICS

Research and Development in Biotechnology (except Nanobiotechnology) (541714)

PSC

HEALTH R&D SERVICES; HEALTH CARE SERVICES; APPLIED RESEARCH (AN12)

Original Source

https://sam.gov/opp/9f5149fe9a04452cabb9dba2d0db66e0/view
Timeline
    Description

    The Department of Health and Human Services, specifically the National Institutes of Health (NIH) through the National Institute of Allergy and Infectious Diseases (NIAID), is soliciting proposals for the development of Radiation/Nuclear Medical Countermeasures (MCMs) and biodosimetry devices. The primary objectives are to create effective MCMs that mitigate normal tissue injuries from ionizing radiation and to advance biodosimetry tools that enhance triage and treatment strategies during radiation emergencies. This initiative is crucial for national preparedness against potential radiological incidents, as it aims to address the urgent need for medical interventions and diagnostic capabilities in mass casualty scenarios. Proposals are due by March 19, 2025, with an estimated funding of $2 million annually for successful applicants over a typical three-year contract period, totaling a possible award of $6 million. For further inquiries, interested parties may contact Albert Nguyen at nguyenal@niaid.nih.gov or Emily Bannister at emily.bannister@nih.gov.

    Point(s) of Contact
    Albert Nguyen
    nguyenal@niaid.nih.gov
    Emily Bannister
    emily.bannister@nih.gov
    Files
    Title
    Posted
    Amendment 1 - BAA-75N93024R00020.pdf
    The document is Amendment No. 1 to Solicitation No. BAA-75N93024R00020, focusing on the development of Radiation/Nuclear Medical Countermeasures (MCMs) and biodosimetry devices. It outlines funding availability and support for proposals aimed at addressing injuries from radiological events, stressing the importance of both effective treatments for radiation exposure and advanced biodosimetry tools that inform medical response strategies. Key points include a $2 million annual funding estimate for successful applicants over a typical contract period of three years, with a total possible award of $6 million. The amendment specifies that MCMs must effectively mitigate radiation injuries long after exposure, particularly for organs not covered by existing FDA-approved treatments. Additionally, it clarifies that repurposing FDA-approved drugs is encouraged and that ornation for interaction or discussions is limited to written submissions only. The overarching aim is to foster the development of innovative solutions capable of mitigating radiation effects and enhancing public health emergency preparedness in large-scale radiation incidents. Thus, the solicitation targets researchers and organizations engaged in medical countermeasures and biodosimetry, aligning with the strategic objectives of the U.S. government in protecting public health against nuclear and radiological threats.
    BAA-75N93024R00020 Development of Radiation Nuclear Medical Countermeasures (MCMs) And Biodosimetry Devices.pdf
    The solicitation outlines a Request for Proposal (RFP) from the National Institute of Allergy and Infectious Diseases (NIAID) for the development of Radiation/Nuclear Medical Countermeasures (MCMs) and biodosimetry devices. The RFP emphasizes two primary goals: creating MCMs to mitigate normal tissue injuries from ionizing radiation and advancing biodosimetry to enhance triage and treatment during radiation emergencies. Proposals must focus on one goal per submission. Submission guidelines state that proposals are due by March 19, 2025, and require registration in the System for Award Management (SAM). The estimated cost and fixed fee for the contract are to be determined (TBD). There are specific reporting requirements, including technical progress reports, which must be submitted electronically and comply with Section 508 requirements for accessibility. Key requirements include the protection of human subjects, adherence to federal regulations on financial conflicts of interest, and compliance with NIH policies promoting transparency in research. The document highlights the necessity for contractors to ensure proper handling of confidential information and human materials and mandates rigorous compliance with applicable laws. Overall, this RFP is a crucial step toward enhancing national preparedness for potential radiological emergencies.
    Presolicitation Notice BAA 75N93024R00020.pdf
    The National Institute of Allergy and Infectious Diseases (NIAID), part of the NIH under DHHS, is announcing a presolicitation for contracts focusing on the "Development of Radiation/Nuclear Medical Countermeasures (MCMs) and Biodosimetry Devices." This initiative aims to create products for assessing and treating radiation injuries from nuclear incidents, preparing them for advanced development through BARDA or the Project BioShield Act. Proposals are sought for candidate devices or MCMs aimed at diagnosing, mitigating, or treating acute radiation syndrome and delayed effects of radiation exposure, with expectations for FDA approval. Evaluation criteria include scientific rigor, technical personnel qualifications, and proposed methodologies, and are expected to span various research stages. NIAID plans to award 1-2 contracts, valued at approximately $6 million over three years, starting around March/April 2026. The submission period opens on/about December 19, 2024, and proposals must be submitted electronically via the NIAID eCPS site. This presolicitation serves the dual goals of enhancing national preparedness and advancing nuclear health technologies, reflecting the government's ongoing efforts to improve responses to public health emergencies involving radiation exposure.
    Similar Opportunities
    2026 NIAID DMID Omnibus Broad Agency Announcement
    Health And Human Services, Department Of
    The Department of Health and Human Services, through the National Institute of Allergy and Infectious Diseases (NIAID), is soliciting proposals for the 2026 DMID Omnibus Broad Agency Announcement (BAA) aimed at advancing research and development of medical countermeasures against antimicrobial-resistant pathogens and viruses with pandemic potential. The BAA encompasses two primary research areas: Research Area 001 focuses on developing therapeutics, vaccines, and diagnostics for antimicrobial-resistant bacterial and fungal pathogens, while Research Area 002 targets the creation of Direct Acting Antivirals for viruses of pandemic potential. This initiative is critical for addressing public health challenges related to infectious diseases, with an estimated funding of $28.5 million available for awards in fiscal year 2026. Proposals for Research Area 001 are due by February 21, 2025, and for Research Area 002 by January 21, 2025; interested parties can contact Swee L. Teo at teosl@niaid.nih.gov or Brian Madgey at brian.madgey@nih.gov for further information.
    Biomedical Advanced Research and Development Authority (BARDA) Broad Agency Announcement (BAA)
    Health And Human Services, Department Of
    The Department of Health and Human Services, through the Biomedical Advanced Research and Development Authority (BARDA), is soliciting proposals under the Broad Agency Announcement (BAA) BAA-23-100-SOL-00004 for advanced research and development of Medical Countermeasures (MCMs) aimed at addressing public health threats such as chemical, biological, radiological, and nuclear (CBRN) incidents, as well as emerging infectious diseases and pandemic influenza. The initiative seeks to foster public-private partnerships to enhance the development and responsiveness of life-saving MCMs, emphasizing the importance of technological maturity, regulatory compliance, and manufacturing standards in the evaluation process. This opportunity is critical for strengthening national health security and improving preparedness for future public health emergencies, with an open submission period running until September 25, 2028, at 4:30 PM Eastern Time. Interested parties can direct inquiries to BARDA-BAA@hhs.gov for further information.
    In Vitro Assessments of Antimicrobial Activity
    Health And Human Services, Department Of
    The National Institutes of Health (NIH), specifically the National Institute of Allergy and Infectious Diseases (NIAID), is seeking proposals for the In Vitro Assessments of Antimicrobial Activity (IVAAA) program through solicitation RFP 75N93024R00024. This initiative aims to support in vitro testing to evaluate the therapeutic potential of compounds against over 270 infectious agents, facilitating the development of vaccines, therapeutics, and diagnostics for infectious diseases. The program is critical for enhancing public health preparedness and response capabilities, particularly in addressing emerging health threats such as bioterrorism and infectious diseases. Proposals are due by March 10, 2025, with a funding range of $2,500 to $15 million available through January 14, 2033. Interested parties can direct inquiries to Alexander Beraud at alexander.beraud@nih.gov or Brian Madgey at brian.madgey@nih.gov.
    Chemistry, Manufacturing and Controls and Related Services for Development of Drug Products
    Health And Human Services, Department Of
    The Department of Health and Human Services, through the National Institutes of Health (NIH), is seeking proposals for Chemistry, Manufacturing, and Controls (CMC) services to support the development of drug products. The objective of this procurement is to ensure the delivery of high-quality formulated drug products for preclinical, IND-enabling, and clinical studies, which are critical for advancing therapeutic development. This opportunity encompasses a wide range of services, including formulation development, manufacturing under current Good Manufacturing Practices (cGMP), and necessary testing to meet regulatory standards. Proposals are due by February 3, 2025, with a contract period extending from September 30, 2025, to July 31, 2031, and a maximum funding amount of $49,885,703. Interested parties can contact Michelle Cecilia at michelle.cecilia@nih.gov or Valerie Whipple at valerie.whipple@nih.gov for further information.
    National Institute of Environmental Health Sciences (NIEHS) Assessment of Immunotoxicity – In Vitro and In Vivo Assessment of Immune Function
    Health And Human Services, Department Of
    The National Institute of Environmental Health Sciences (NIEHS), part of the Department of Health and Human Services, is seeking proposals for a contract focused on the assessment of immunotoxicity through both in vitro and in vivo studies of immune function. The primary objective is to evaluate how selected chemical agents modify immune responses, utilizing established testing models to enhance understanding of immunotoxicity while aiming to reduce animal use in research. This initiative is critical for advancing toxicological assessments and ensuring compliance with federal standards in environmental health research. Interested contractors must submit their proposals by 4:00 PM EST on February 18, 2025, and can direct inquiries to Adam Muhsin at adam.muhsin@nih.gov or Erica Kitzmiller at erica.kitzmiller@nih.gov.
    In Vivo Non-Invasive Optical Imaging Approaches for Biological Systems (UG3/UH3 Clinical Trials Not Allowed
    Health And Human Services, Department Of
    The Department of Health and Human Services, specifically the National Institutes of Health (NIH), is seeking innovative proposals for the development of In Vivo Non-Invasive Optical Imaging Approaches for Biological Systems. The initiative aims to address the challenges posed by light scattering in biological tissues, which currently limits the effectiveness of non-invasive optical imaging techniques in assessing tissue function and structure. This funding opportunity encourages the advancement of next-generation imaging technologies that can achieve deeper penetration and higher resolution in biological systems. Interested applicants should note that the application due date is March 7, 2025, by 5:00 PM local time, and are encouraged to submit a letter of intent by the same date. For further inquiries, contact Jonathan Pollock at jpollock@mail.nih.gov or Robert Bailey at rob.bailey@nih.gov.
    Maintenance and Service Agreement for Varian TrueBeam/ARIA/Eclipse Radiation Therapy System
    Health And Human Services, Department Of
    The Department of Health and Human Services, through the National Institutes of Health (NIH) and the National Cancer Institute (NCI), is seeking to establish a Maintenance and Service Agreement for its Varian TrueBeam/ARIA/Eclipse Radiation Therapy System. The procurement aims to secure maintenance and upgrade services from Varian Medical Systems, Inc., the Original Equipment Manufacturer (OEM), ensuring compliance with federal safety regulations and maintaining a minimum operational uptime of 97% for the systems. This equipment is vital for the Center for Cancer Research to conduct clinical and pre-clinical research in radiation oncology, and the contract will include provisions for preventive maintenance, emergency services, and software updates. Interested parties may submit proposals by January 27, 2025, to the designated Contracting Officer, John Russell, at john.russell3@nih.gov, with all contractors required to be registered in SAM.GOV for award eligibility.
    AMENDMENT 0001: Reactor Recovery Services
    Commerce, Department Of
    The National Institute of Standards and Technology (NIST), part of the Department of Commerce, is soliciting proposals for an Indefinite Delivery, Indefinite Quantity (IDIQ) contract for Reactor Recovery Services, following contamination issues at its facility. The contract, valued at up to $9 million over four years, requires contractors to provide labor, materials, and logistical support for tasks such as fuel transfer chute replacement, hot spot removal, inspections, and waste disposal, all while adhering to stringent safety and compliance standards. This procurement is critical for maintaining safety in nuclear operations and ensuring environmentally responsible recovery practices. Interested bidders must submit questions by January 22, 2025, and request access to additional documents by January 15, 2025, with inquiries directed to Contract Specialist Cielo Ibarra at cielo.ibarra@nist.gov.
    Toxicity testing on a new PET ligand (Sources Sought)
    Health And Human Services, Department Of
    The Department of Health and Human Services, specifically the National Institutes of Health (NIH), is seeking qualified contractors to conduct a toxicity study on a new PET ligand, Fluorine-18-Fluorocellobiose, as part of the Investigational New Drug (IND) application process. The project entails performing a single-dose toxicity study on Sprague Dawley rats, adhering to FDA's Good Laboratory Practice (GLP) standards, with the aim of assessing toxicity endpoints and developing analytical methods for drug level evaluation. This initiative underscores NIH's commitment to advancing biomedical research while ensuring compliance with regulatory requirements in drug development. Interested parties must submit their responses, including company information and capability statements, to Grace Wong-Darko at Grace.Wong-Darko@nih.gov by 1:00 PM EST on January 31, 2025.
    MTEC Solicitation Summary: Fiscal Year 2025 Multi Topic Request for Proposals
    Dept Of Defense
    The Department of Defense, through the Medical Technology Enterprise Consortium (MTEC), is soliciting proposals for the Fiscal Year 2025 Multi Topic Request for Proposals (RPP) aimed at developing innovative medical technologies relevant to military operations. The RPP focuses on a variety of medical prototype solutions addressing battlefield injuries and infections, with specific areas of interest including prophylactics for infection, treatment countermeasures for sepsis, antivirals, musculoskeletal injuries, and sterilization solutions. This initiative is critical for enhancing medical capabilities to ensure force readiness and soldier lethality in future conflicts. Interested parties must submit Enhanced White Papers addressing a single focus area, with funding amounts ranging from approximately $750K to $5M depending on the project scope, and proposals are due as specified on the MTEC website. For further inquiries, contact Chuck Hutti at chuck.hutti@ati.org or 843-760-3795.